Cantor Fitzgerald Analysts Give Arrowhead Pharmaceuticals (ARWR) a $2.00 Price Target

Cantor Fitzgerald set a $2.00 price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report released on Tuesday. The brokerage currently has a hold rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on ARWR. ValuEngine raised Arrowhead Pharmaceuticals from a strong sell rating to a sell rating in a report on Monday, October 2nd. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price objective on the stock in a report on Monday, November 27th. BidaskClub downgraded Arrowhead Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, December 2nd. William Blair raised Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. Finally, Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $3.17.

Arrowhead Pharmaceuticals (ARWR) traded down $0.25 during midday trading on Tuesday, hitting $3.15. The company had a trading volume of 1,702,100 shares, compared to its average volume of 984,368. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.84 and a current ratio of 3.63. Arrowhead Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $4.54.

A number of large investors have recently made changes to their positions in the stock. ING Groep NV bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $3,500,000. Geode Capital Management LLC raised its position in shares of Arrowhead Pharmaceuticals by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 21,654 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $1,958,000. LMR Partners LLP bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $467,000. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Arrowhead Pharmaceuticals by 10.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after acquiring an additional 16,103 shares in the last quarter. 20.20% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://sportsperspectives.com/2017/12/15/cantor-fitzgerald-analysts-give-arrowhead-pharmaceuticals-arwr-a-2-00-price-target.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply